Glaxo Avandia Restrictions Should Be Eased, Panel Says

The perceived heart risks that torpedoed sales of GlaxoSmithKline Plc’s best-selling diabetes pill Avandia may have been overstated and restrictions on prescribing the drug should be eased, U.S. advisers said.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.